Claims for Patent: 6,982,283

Summary for Patent: 6,982,283

Title:	Method for treating drug-induced constipation
Abstract:	Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.
Inventor(s):	Ueno; Ryuji (Montgomery, MD)
Assignee:	Sucampo AG (Zug, CH)
Application Number:	10/135,397
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,982,283
Patent Claims:	1. A method for treating drug-induced constipation comprising a step of administering an effective amount of 15-keto-prostaglandin compound to a subject suffering from drug-induced constipation or in need thereof of such treatment, wherein the 15-keto-prostaglandin compound is one represented by formula (I): ##STR00006## wherein L,M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy(lower)alkyl or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond; A is --CH.sub.2OH, --COCH.sub.2OH, --COOH or a functional derivative thereof; B is --CH.sub.2--CH.sub.2--, --CH.dbd.CH-- or --C.ident.C--; R.sub.1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; heterocyclic-oxy group. 2. The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-prostaglandin compound. 3. The method of claim 1, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono- or di-halogen-prostaglandin compound. 4. The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono- or di-halogen-prostaglandin compound. 5. The method of claim 2, wherein the 15-keto-prostaglandin compound is a 15-keto-16-mono- or di-fluoro-prostaglandin compound. 6. The method of claim 2, wherein the 15-keto prostaglandin compound is a 13,14-dihydro-15-keto-16-mono- or di-fluoro-prostaglandin compound. 7. The method of claim 2, wherein the 15-keto-prostaglandin compound is a 15-keto-prostaglandin E compound. 8. The method of claim 2, wherein the 15-keto-prostaglandin compound is 13,14-dihydro-15-keto-16, 16-difluoro-prostaglandin E.sub.1. 9. The method of claim 2, wherein the drug inducing constipation is an opioid compound. 10. The method of claim 9, wherein the opioid compound is a morphine compound or a codeine compound. 11. The method of claim 1, wherein the drug inducing constipation is an anticholinergic drug. 12. The method of claim 11, wherein the anticholinergic drug is a tricyclic antidepressant.